scholarly journals Botulinum Toxin Treatment Practice Recommendations for Movement Disorders Clinics During the COVID-19 Pandemic

2021 ◽  
Keyword(s):  
Botulinum Toxin ◽  
Movement Disorders ◽  
Treatment Practice ◽  
Practice Recommendations ◽  
Botulinum Toxin Treatment

scholarly journals Patient Knowledge, Attitude and Perceptions towards Botulinum Toxin Treatment for Movement Disorders in India

2021 ◽  
Author(s):  
Thavasimuthu Nisha Mol ◽  
Nitish Kamble ◽  
Vikram V. Holla ◽  
Rohan Mahale ◽  
Pramod Kumar Pal ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Movement Disorders ◽  
Patient Knowledge ◽  
Botulinum Toxin Treatment

scholarly journals Laryngeal electromyography in movement disorders: preliminary data

2004 ◽  
Vol 62 (3a) ◽  
pp. 741-744 ◽  
Author(s):  
Paulo A.T. Kimaid ◽  
Elizabeth M.A.B. Quagliato ◽  
Agrício N. Crespo ◽  
Aline Wolf ◽  
Maura A. Viana ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Tourette Syndrome ◽  
Movement Disorders ◽  
Preliminary Data ◽  
Spasmodic Dysphonia ◽  
Laryngeal Electromyography ◽  
Botulinum Toxin Therapy ◽  
Monopolar Electrodes ◽  
Botulinum Toxin Treatment ◽  
Vocal Tremor

This study describes preliminary laryngeal electromyography (LEMG) data and botulinum toxin treatment in patients with dysphonia due to movement disorders. Twenty-five patients who had been clinically selected for botulinum toxin administration were examined, 19 with suspected laryngeal dystonia or spasmodic dysphonia (SD), 5 with vocal tremor, and 1 with Gilles de la Tourette syndrome (GTS). LEMG evaluations were performed before botulinum toxin administration using monopolar electrodes. Electromyography was consistent with dystonia in 14 patients and normal in 5, and differences in frequency suggesting essential tremor in 3 and Parkinson tremors in 2. The different LEMG patterns and significant improvement in our patients from botulinum toxin therapy has led us to perform laryngeal electromyography as a routine in UNICAMP movement disorders ambulatory.

scholarly journals Botulinum Toxin in Movement Disorders: An Update

Toxins ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 42
Author(s):  
Charenya Anandan ◽  
Joseph Jankovic
Keyword(s):  
Botulinum Toxin ◽  
Movement Disorders ◽  
Neurological Disorders ◽  
Active Drug ◽  
Therapeutic Agents ◽  
Therapeutic Modality ◽  
Review Of The Literature ◽  
Pilot Studies ◽  
The Us ◽  
Novel Applications

Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological disorders. With respect to neurologic movement disorders, BoNT has been reported to be effective for the treatment of dystonia, bruxism, tremors, tics, myoclonus, restless legs syndrome, tardive dyskinesia, and a variety of symptoms associated with Parkinson’s disease. More recently, research with BoNT has expanded beyond its use as a powerful muscle relaxant and a peripherally active drug to its potential central nervous system applications in the treatment of neurodegenerative disorders. Although BoNT is the most potent biologic toxin, when it is administered by knowledgeable and experienced clinicians, it is one of the safest therapeutic agents in clinical use. The primary aim of this article is to provide an update on recent advances in BoNT research with a focus on novel applications in the treatment of movement disorders. This comprehensive review of the literature provides a critical review of evidence-based clinical trials and highlights recent innovative pilot studies.

Sign in / Sign up

Export Citation Format

Share Document